A new drug is able to defeat breast cancer
Scientists of the Mayo Clinic reports that Z-endoxifene safely and effectively reduces tumors in women with ER-positive metastatic breast cancer. As UPI.com notices Z-endoxifene is a powerful derivative of tamoxifen, another drug for ER-positive metastatic breast cancer.
In the liver tamoxifen is converted to endoxifene due to CYP2D6 action. Previous studies have shown that the effectiveness of tamoxifen is lower when a woman has problems with CYP2D6 metabolism. The new study involved 41 women with ER-positive metastatic breast cancer.
Standard methods of treatment did not help the participants. The researchers have found that Z-endoxifene fought against the participants’ tumors successfully. Its effectiveness did not depend on CYP2D6 metabolism. The toxicity of the drug was acceptable. In some cases the anticancer effect has persisted for more than two years.